SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following its CEO's significant presentation at a major cancer summit outlining breakthroughs in 'chemo-free' treatments and recent international regulatory approvals for its ANKTIVA therapy. The community is actively discussing the stock's "unstoppable" scientific progress and the potential for a substantial short squeeze fueled by high short interest.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical ($DRTS) is trending as the community anticipates imminent Japanese marketing approval for its Alpha DaRT cancer treatment, further validated by successful glioblastoma patient outcomes and growing institutional interest, positioning the company for significant global commercial expansion.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trump's State of the Union address is driving immediate conversation around DJT, generating intensely polarized reactions with supporters praising his "epic" speech while detractors label it a "clown show" "full of lies." Community discussions actively center on his policy claims regarding tariffs, immigration, and the economy, alongside renewed chatter on Epstein-related allegations.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending as Paramount Skydance's significantly revised all-cash offer, now at $31 per share plus a ticking fee and commitment to cover Netflix's breakup cost, has prompted WBD's board to consider it a potentially superior proposal. The community is sharply divided on whether Netflix will increase its own complex bid or opt to accept the breakup fee amidst mounting regulatory concerns and debt implications.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the bidding war for Warner Bros. Discovery intensifies with Paramount's revised offer, igniting strong community discussion on whether Netflix should raise its bid or walk away to collect a substantial breakup fee, all while facing heightened regulatory and political pressure.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending due to upcoming earnings and intense debate surrounding the CLARITY Act's impact on stablecoin yields, with bulls highlighting growing institutional adoption and USDC's foundational role while bears cite regulatory uncertainty, past insider selling, and its price correlation to broader crypto market volatility.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as Warner Bros. Discovery re-evaluates its acquisition offers, granting a limited waiver to re-engage with PSKY following its revised, all-cash bid including substantial regulatory breakup and ticking fees. The community is actively discussing PSKY's offer as potentially superior against Netflix's, while also weighing concerns about the massive debt PSKY would incur if successful.

HP Inc. is an information technology company, which engages in the provision of personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services. It operates through the following segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, solutions and services, and scanning devices. The Corporate Investments segment includes HP Labs and certain business incubation projects. The company was founded by William R. Hewlett and David Packard in 1939 and is headquartered in Palo Alto, CA.

HP Inc

HP Inc. is trending as its latest earnings report paints a divided picture for investors, with weak near-term profit guidance, impacted by U.S. tariffs and supply chain shifts, sparking bearish concerns. Conversely, many in the community are emphasizing the company's compelling value, robust free cash flow, and recently increased dividend, alongside the long-term growth prospects from AI-powered PCs.

Fortuna Mining Corp. engages in the exploration, extraction and processing of precious and base metal in Latin America. It operates through the following segments: Minera Bateas S.A.C (Bateas), Compania Minera Cuzcatlan S.A. de C.V. (Cuzcatian), Mansfield Minera S.A. (Mansfield), and Corporate. The Beates segment operates the Caylloma silver, lead, and zinc mine. The Cuzcatlan segment handles the San Jose silver-gold mine. The Mansfield segment constructs the Lindero mine. The Corporate segment represents the corporate stewardship. The company was founded by Jorge Alberto Ganoza Durant, Simon T. P. Ridgway, and Mario David Szotlender on September 4, 1990 and is headquartered in Vancouver, Canada.

Fortuna Mining Corp.

Fortuna Silver Mines Inc.

Fortuna Silver Mines (FSM) is a trending topic following recent positive exploration results at its Diamba Sud Gold Project and strong cash flow from its latest earnings, alongside strategic asset sales. Despite the backdrop of 'flying' gold and silver prices, community sentiment is mixed, with many highlighting the stock's perceived undervaluation while others voice frustration over its lagging market performance.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

Cava Group is trending following its earnings report, which showcased robust revenue growth and restaurant expansion, pushing its annual revenue past $1 billion. The community is actively debating the company's valuation and decelerating same-store sales against its ambitious growth plans and strong digital performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

Equity

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.


<ul class="summary-bullets"><li>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.</li><li>Nektar stated that patients receiving monthly and quarterly dosing regimens resulted in sustained disease control for EASI-75, EASI-90, and other indicators.</li><li>The company also noted that it observed an increase in patients who achieved EASI-100 in the 24 micrograms per kilogram dosing regimens in the monthly and quarterly time periods.</li></ul>Nektar Therapeutics Inc. (NKTR) shares rose more than 42% in Tuesday’s opening trade after the company reported positive results from its long-term atopic dermatitis trial.Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/NKTR">Nektar Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels. The NKTR stock was among the top ten trending tickers on the platform.<h2 class="st-heading-2">Nektar’s Findings In The Trial</h2>The company stated that the global REZOLVE-AD Phase 2b study included 393 patients with moderate-to-severe atopic dermatitis.Nektar stated that patients receiving monthly and quarterly dosing regimens achieved sustained disease control as measured by EASI-75, EASI-90, the validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and the Itch Numerical Rating Scale (NRS) response.The company also noted an increase in patients achieving EASI-100 on the 24 micrograms per kilogram dosing regimens during the monthly and quarterly periods.EASI refers to the Eczema Area and Severity Index. It quantifies the severity and extent of eczema symptoms across body regions. EASI-75 points to a greater than or equal to 75% improvement from baseline, while EASI-90 refers to a 90% or more improvement. Similarly, EASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">Retail Gives A Thumbs Up</h2>One bullish user observed that “patience does pay off,” while adding that they are not selling the stock.<stembedurl>https://stocktwits.com/aristocks/message/644554531</stembedurl>Another user stated that there is nothing to “even remotely” criticize Nektar for, following the announcement of the trial results.<stembedurl>https://stocktwits.com/clarksonhockey/message/644552638</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up 24% year-to-date and 204% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-fisv-stock-falling-today/cZbU3sOR4Yp">Why Is FISV Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

<ul class="summary-bullets"><li>Anaphylm is Aquestive’s sublingual epinephrine film for allergic reactions.</li><li>The Anaphylm application is supported by 11 clinical studies involving 411 subjects, the company said.</li><li>Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA date on January 31, it added.</li></ul>Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that currently prevent labeling discussions on Anaphylm.Anaphylm is Aquestive’s sublingual (under the tongue) epinephrine film for allergic reactions.However, the FDA also confirmed its review of the New Drug Application (NDA) remains ongoing, and no final decision has been made.Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA (Prescription Drug User Fee Act) date on January 31, noting that delays in receiving details could impact the approval timeline. A PDUFA date is the FDA's target date to make a decision on a drug application.The Anaphylm application is supported by 11 clinical studies involving 411 subjects, demonstrating pharmacokinetics comparable to epinephrine auto-injectors and a similar safety profile, Aquestive added.“As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time. Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns. The FDA stated that the notification does not reflect a final decision on the pending application and the FDA’s review remains ongoing,” said Dan Barber, President and Chief Executive Officer of Aquestive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the strong intraday decline, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/AQST">AQST</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_2de986106b.webp" alt="AQST.jpg">Over the past year, the stock has gained 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Plug Power said it was impacted by the speed and development of hydrogen economy.

Why Did AQST Stock Plunge 40% In Pre-Market Today?

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed 

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

<ul class="summary-bullets"><li>The interim data show that ARO-INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat.</li><li>In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.</li><li>ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans.</li></ul>Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 15% in Tuesday’s premarket, after it released early data from its Phase 1/2a clinical trials of its RNA interference (RNAi) therapies, ARO-INHBE and ARO-ALK7, targeting obesity.&nbsp;The preliminary results suggest these investigational treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.<h2 class="st-heading-2">Promising Fat Reduction</h2>The interim data show that ARO-INHBE, especially when combined with tirzepatide, a GLP-1/GIP receptor co-agonist, doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared with tirzepatide alone.The findings mark the first human evidence that targeting the Activin E/ALK7 pathway could enhance weight loss beyond that achieved by existing incretin therapies. In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.On Stocktwits, retail sentiment around Arrowhead stock jumped to ‘bullish’ from ‘bearish’ territory. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_081204_png_73fc92d26b.webp" alt="ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Clinical Highlights</h2>ARO-INHBE monotherapy at week 16 led to a 9.9% reduction in visceral fat, a 38% drop in liver fat, and a 3.6% increase in lean muscle. Two doses at week 24 further improved visceral fat reduction to 15.6% after adjusting for placebo.&nbsp;Combined with tirzepatide, ARO-INHBE achieved roughly double the weight loss and triple the fat reduction compared to tirzepatide alone.ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans, reducing ALK7 mRNA in fat tissue by an average of 88% at the 200 mg dose, with a peak reduction of 94%. Early data also showed a 14.1% reduction in visceral fat after a single dose at week 8, adjusted for placebo.ARWR stock has gained over 227% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-draws-bullish-retail-chatter-ahead-of-key-investor-event-trader-calls-it-potential-multibagger/cmxwMoyR4T0">Ondas Stock Draws Bullish Retail Chatter Ahead Of Key Investor Event – Trader Calls It ‘Potential Multibagger’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

Why Did ARWR Stock Surge Over 15% Pre-Market Today? 

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.

3 Undervalued ETFs to Buy Before 2026

Worried about high valuations? KBE, XRT, and XPH with low P/Es and fresh momentum are three undervalued ETFs to consider as 2026 approaches.

Pharma ETF (XPH) Hits a New 52-Week High

Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?

SPDR Series Trust - State Street SPDR S&P Pharmaceuticals ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

XPH
SPDR Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XPH News

XPHSPDR Pharmaceuticals ETF